Clinical Trial Update: Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents [Phase 1]

View source ↗

Summary

Phase 1 results assess safety and preliminary efficacy of combining pembrolizumab with entinostat in patients with myelodysplastic syndrome who are non-responsi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Entinostat (entinostat)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED | Results posted: 2024-10-01